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Abstract 
Six homoleptic Ti(IV) compounds of dianionic tridentate Schiff base ligands were 
synthesized from chiral amino acids, 2-hydroxybenzaldehyde and Ti(OiPr)4. The 
compounds were spectroscopically characterized and the molecular geometries were 
established by X-ray crystallography. The ligands coordinated the titanium via 
carboxylate-O-, imine-N-, and phenoxide-O atoms. Two isomers were identified; 
each based on a trans-N2O4 donor set, but one with trans carboxylate-O atoms and 
another with each carboxylate-O atom trans to a phenoxide-O atom. Photophysical 
profiles exhibited faster excited-state relaxation in the solid phase than in solution. 
Marked cytotoxicities were recorded toward human ovarian A2780 and colon HT-29 
cancer cells with IC50 values ranging between 23±2 and 103±3 µM. Comparative 
hydrolytic stability studies by NMR in 10% D2O solutions provided t1/2 values of up to 
15±2 h, with little correlation to cytotoxicity implying a role of hydrolysis products in 
the reactivity and identifying steric bulk as a contributor to stability and solubility.  
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Introduction 
The licensing of cisplatin in the 1970s has initiated a widespread search for other 
anticancer metallodrugs that could overcome its toxicity and acquired-resistance 
properties.[1–3] Other metals were proposed, among which titanium is a promising 
candidate due to its biocompatibility.[4-25] Two titanium(IV)-based complexes, 
budotitane and titanocene dichloride, were the first non-platinum metallodrugs to 
enter clinical trials. They failed due to low water solubility and rapid hydrolysis, which 
required high doses of administration ultimately leading to insufficient efficiency.[26,27] 
Our group has introduced a new class of Ti(IV) complexes, based on phenolato 
ligands. The first generation comprised diaminobis(phenolato) tetradentate ligands, 
with two labile alkoxo ligands per metal center.[28] The complexes of this class 
exhibited in vitro and in vivo cytotoxicity toward cancer cells and relatively high 
hydrolytic stability, and were therefore widely explored.[29-47] Further stabilization was 
achieved upon the employment of hexadentate derivatives of the phenolato ligands, 
leading to highly cytotoxic complexes that were stable for weeks in water.[34,48–52] 
These observations, along with other reports of inert Ti(IV) complexes with 
anticancer properties,[53–55] indicate that the labile ligands are not required for 
antiproliferative effects. Consequently, we have recently reported the synthesis of 
eight Ti(IV) complexes with two dianionic tridentate acylhydrazone ligands, which 
showed high hydrolytic stability and cytotoxicity comparable to that of cisplatin.[56] 
Amino acids and their derivatives have been extensively used as ligands in metal 
complexes for various purposes, such as catalysis, labeling, amino acid and peptide 
synthesis, and pharmaceutical applications.[57] Specifically, the use of amino acids in 
ligands for anticancer metal complexes has been established since the clinical 
development of cisplatin, for two main reasons.[58] First, amino acids are biological 
materials that enter cells through active-transport mechanisms,[59,60] making the 
complexes biocompatible and reducing the chances for developing resistance. 
Second, given the extensive proliferative rates of cancer cells, their requirements for 
metabolites such as amino acids are greater than the needs of normal cells, which 
may cause cancer cells to mistake the ligands for natural amino acids, hindering 
further proliferation.[61–63] Numerous examples of amino acid-based anticancer metal 
complexes exist in the literature, including titanium,[64] zirconium,[65] palladium,[66] 
ruthenium,[67] and tin complexes.[68–71] 
Herein, we present six novel Ti(IV) complexes, all composed of tridentate amino 
acid-tethered phenolato ligands. The amino acids applied in this study were of a 
hydrophobic nature, in the hope of accelerating the penetration of cellular 
membranes by the complexes. We describe the synthesis and characterization of the 
complexes and analyze their hydrolytic stability and cytotoxicity toward two cancer 
cell lines. 
  
Experimental section 
Materials and physical measurements  
Titanium(IV) tetra(isopropoxide), L-alanine, L-valine, L-isoleucine, L-leucine, D,L-
phenylalanine, L-tryptophan, salicylaldehyde were purchased from SRL and used 
without further purification. Solvents used were of A. R. grade and dried using 
standard procedures. Benzene, toluene and hexane were distilled from 
benzophenone/sodium, whereas methanol and dichloromethane were distilled over 
activated magnesium and calcium hydride, respectively. All manipulations were 
performed using standard Schlenk lines in an atmosphere of dry dinitrogen or 
argon, unless otherwise stated. Note: Reactions can be conducted in toluene, 
however, synthetic conveniences, particularly the higher boiling point of toluene, led 
to the choice of benzene. Care in handling benzene should be exercised. 
Melting points were measured using a Büchi M-560 instrumentation. Elemental 
analyses were performed using a Perkin Elmer 2400 series II instrument. IR spectra 
in the range 4000-400 cm-1 were obtained as KBr discs on a Bruker ALPHA II FT-IR 
spectrophotometer. Solution 1H and 13C{1H} NMR spectra in CDCl3, measured at 
400.13 and 100.62 MHz respectively, were recorded on a Bruker AMX 400 
spectrometer. The 1H and 13C chemical shifts were referenced to Me4Si (δ 0.00 ppm) 
and CDCl3 (δ 77.00 ppm), respectively. The UV-visible absorption and fluorescence 
measurements of the samples dissolved in spectroscopic grade DMSO and 
acetonitrile (concentration ca. 50 µM) were taken in PerkinElmer model Lambda25 
and Quanta master (QM-40) steady-state fluorescence apparatus supplied by Photon 
Technology International (PTI), respectively. Spectra were calibrated by subtracting 
the solvent as blank control measured in the same condition. Photoluminescence 
spectra in the solid-state were measured by using a special solid-state sample holder 
(part no. 557820058) supplied by PTI in the same instrument. Fluorescence lifetime 
measurements of the samples were performed by exciting either at 295 nm or 365 
nm in an LED-based time-correlated single photon counting (TCSPC) system (PM-3) 
supplied by PTI. The fluorescence decay spectra of the samples were collected at 
magic angles. Other details pertaining to fluorescence experiments and calculations 
are given in the supplementary materials (ESI Text S1).  
 
Synthesis of titanium(IV) complexes 1-6 
 
Titanium(IV) complexes 1-6 (Scheme 1) were prepared by separately reacting amino 
acids (L-alanine, L-valine, L-isoleucine, L-leucine, D,L-phenylalanine and L-
tryptophan), 2-hydroxybenzaldehyde and titanium(IV) tetra(isopropoxide) in 2:2:1 
molar ratio. Complexes 1-6 were prepared following a similar synthetic route and 
hence a detailed typical procedure for 1 is outlined below. 
 
Synthesis of 1. Titanium(IV) tetra(isopropoxide) (0.25 g, 0.879 mmol) was added 
drop-wise to a stirred benzene suspension (30 ml) containing finally ground L-alanine 
(0.15 g, 1.759 mmol) and 2-hydroxybenzaldehyde (0.21 g, 1.758 mmol). The reaction 
mixture slowly turned pale yellow, followed by heating to reflux for 45 minutes at 80 
°C on an oil bath with continuous stirring. To this reaction mixture, 5 ml of methanol 
was added to aid the solubility and reflux was continued for an additional 8 h. A clear 
orange solution was filtered while hot and the filtrate was concentrated under 
reduced pressure. Pasty material was boiled with hexane, filtered, and the solid mass 
was dried in vacuo. The yellow powder was dissolved in 5 ml of hot chloroform, 
filtered, and the filtrate was concentrated up to 2 ml, which was precipitated with 
hexane. The precipitate was filtered, washed several times with hot hexane, and 
dried in vacuo. Recrystallization from a benzene/ methanol mixture (3:1 ratio) 
afforded orange crystals suitable for single crystal XRD. Yield: 0.28 g, 74%. m.p. 
303-306 °C; 1H NMR (400 MHz, CDCl3): δ=8.51 (s, 2H; H-7), 7.52-7.44 (m, 4H; H-3 
and H-5), 7.00 (t, 2H; H-4), 6.65 (d, 2H; H-2), 4.68 (q, 2H; H-9), 1.69 ppm (d, 3JH,H=8 
Hz, 6H; H-11); 13C NMR (100 MHz, CDCl3): δ=176.4 (C-10), 165.1 (C-7), 162.3 (C-1), 
137.3 (C-3), 134.4 (C-5), 122.2 (C-6), 121.8 (C-2), 115.8 (C-4), 71.0 (C-9), 21.6 ppm 
(C-11); IR (KBr): ν~=1696 (OCO)asym, 1608 (C=N), 1551, 1474, 1448, 1396 (OCO)sym, 
1370, 1290, 1246, 1156, 1130, 1051, 912, 822, 759, 645, 566 cm-1; elemental 
analysis calcd (%) for C20H18N2O6Ti: C 55.83, H 4.22, N 6.51; found: C 56.13, H 4.44, 
N 6.14. 
Synthesis of 2. An analogous method to that used for the preparation of 1 was 
followed using titanium(IV) tetra(isopropoxide) (0.25 g, 0.879 mmol), L-valine (0.20 g, 
1.759 mmol) and 2-hydroxybenzaldehyde (0.21 g, 1.758 mmol), giving orange 
crystals of 2 from a toluene/ dichloromethane/ methanol (v/v, 2:1:1) mixture in a yield 
of 0.31g, 72%. The crystals turned into powder with time. For diffraction studies, 
crystals of 2 were recrystallized from ethanol and stored in silicon oil. m.p. 309-312 
°C; 1H NMR (400 MHz, CDCl3): δ=8.43 (s, 2H; H-7), 7.54-7.49 (m, 4H; H-3 and H-5), 
7.02 (t, 2H; H-4), 6.60 (d, 2H; H-2), 4.39 (d, 2H; H-9), 2.33 (m, 2H; H-11), 1.11 (d, 
3JH,H=6.8 Hz, 6H; H-12a), 1.06 ppm (d, 3JH,H=6.8 Hz, 6H; H-12b); 13C NMR (100 MHz, 
CDCl3): δ=174.8 (C-10), 165.6 (C-7), 162.4 (C-1), 137.3 (C-3), 134.6 (C-5), 122.4 (C-
2), 121.8 (C-4), 115.7 (C-6), 80.9 (C-9), 36.0 (C-11), 18.7 (C-12a), 18.3 ppm (C-12b) 
ppm; IR (KBr): ν~=1701 (OCO)asym, 1605 (C=N), 1551, 1470, 1446, 1399 (OCO)sym, 
1284, 1152, 1126, 1031, 906, 820, 762, 643, 594, 567 cm-1; elemental analysis calcd 
(%) for C24H26N2O6Ti: C 59.27, H 5.39, N 5.76; found: C 59.55, H 5.98, N 5.30. 
Synthesis of 3. An analogous method to that used for the preparation of 1 was 
followed using titanium(IV) tetra(isopropoxide) (0.25 g, 0.879 mmol), L-isoleucine 
(0.23 g, 1.759 mmol) and 2-hydroxybenzaldehyde (0.21 g, 1.758 mmol), giving 
orange crystals of 3 from a chloroform/ethanol (v/v, 3:1) mixture in a yield of 0.32 g, 
70%. The crystals turned into powder with time. For diffraction studies, crystals of 3 
were recrystallized from ethanol and stored in silicon oil. m.p. 292-295 °C; 1H NMR 
(400 MHz, CDCl3): δ=8.43 (s, 2H; H-7), 7.54-7.48 (m, 4H; H-3 and H-5), 7.02 (t, 2H; 
H-4), 6.60 (d, 2H; H-2), 4.49 (d, 2H; H-9), 1.96 (m, 2H; H-11), 1.73-1.68 (m, 2H; H-
12a), 1.47-1.41 (m, 2H; H-12b), 1.05 (d, 3JH,H= 6.5 Hz, 6H; H-14), 0.94 ppm (t, 3JH,H= 
7 Hz, 6H; H-13). 13C NMR (100 MHz, CDCl3): δ=174.5 (C-10), 165.3 (C-7), 162.4 (C-
1), 137.1 (C-3), 134.5 (C-5), 122.4 (C-2), 121.7 (C-4), 115.6 (C-6), 79.6 (C-9), 43.7 
(C-11), 25.8 (C-12), 14.7 (C-14), 12.1 ppm (C-13); IR (KBr): ν~=1699 (OCO)asym, 
1604 (C=N), 1550, 1445, 1402 (OCO)sym, 1285, 1231, 1152, 1127, 969, 943, 828, 
760, 641, 569 cm-1; elemental analysis calcd (%) for C26H30N2O6Ti: C 60.71, H 5.88, 
N 5.45; found: C 61.22, H 5.80, N 5.55. 
Synthesis of 4. An analogous method to that used for the preparation of 1 was 
followed using titanium(IV) tetra(isopropoxide) (0.25 g, 0.879 mmol), L-leucine (0.23 
g, 1.759 mmol) and 2-hydroxybenzaldehyde (0.21 g, 1.758 mmol), giving orange 
crystals of 4 from ethanol in a yield of 0.29 g, 64%. The crystals turned into powder 
with time. For diffraction studies, crystals of 4 were stored in silicon oil. m.p. 202-204 
°C; 1H NMR (400 MHz, CDCl3): δ=8.44 (s, 2H; H-7), 7.61-7.57 (m, 4H; H-3 and H-5), 
7.12-7.08 (m, 2H; H-4), 6.71 (d, 2H; H-2), 4.64 (m, 2H; H-9), 2.07 (m, 2H; H-11), 1.87 
(m, 4H; H-12), 1.03 ppm (brd, 12H; H-13a and 13b); 13C NMR (100 MHz, CDCl3): 
δ=175.1 (C-10), 164.0 (C-7), 161.8 (C-1), 136.8 (C-3), 133.9 (C-5), 121.7 (C-2), 121.4 
(C-4), 115.3 (C-6), 73.9 (C-9), 44.1 (C-12), 23.4 (C-11), 22.3 (C-13b), 22.1 ppm (C-
13a); IR (KBr): ν~=1699 (OCO)asym, 1607 (C=N), 1551, 1470, 1446, 1399 (OCO)sym, 
1283, 1151, 1124, 913, 865, 820, 759, 641, 571 cm-1; elemental analysis calcd (%) 
for C26H30N2O6Ti: C 60.71, H 5.88, N 5.45; found: C 61.10, H 6.02, N 5.44. 
Synthesis of 5. An analogous method to that used for the preparation of 1 was 
followed using titanium(IV) tetra(isopropoxide) (0.25 g, 0.879 mmol), D,L-
phenylalanine (0.29 g, 1.759 mmol) and 2-hydroxybenzaldehyde (0.21 g, 1.758 
mmol), giving fine orange crystals of 5 (m.p. 268-270 °C) from a chloroform/hexane 
(v/v, 3:1) mixture. These crystalline materials were recrystallized from toluene, which 
provided diffraction quality crystals in a yield of 0.35 g, 68% . The crystals turned into 
powder with time. For diffraction studies, crystals of 5 were stored in silicon oil. m.p. 
298-300 °C; 1H NMR (400 MHz, CDCl3): δ=8.27 (s, 2H; H-7), 7.62 (t, 2H; H-3), 7.48 
(d, 2H; H-5), 7.25 (m, 6H; H-14, H-15 and H-16), 7.15 (m, 4H; H-13 and H-17), 7.08 
(t, 2H; H-4), 6.65 (d, 2H; H-2), 4.97 (q, 2H; H-9), 3.48 (dd, 2H; H-11a), 3.14 ppm (dd, 
2H, H-11b); 13C NMR (100 MHz, CDCl3): δ=175.0 (C-10), 164.8 (C-7), 162.1 (C-1), 
137.1 (C-3), 135.7 (C-12), 134.2 (C-5), 130.3 (C-14 and C-16), 129.1 (C-13 and C-
17), 127.6 (C-15), 121.9 (C-2), 121.6 (C-4), 115.7 (C-6), 78.1 (C-9), 40.9 ppm (C-11); 
IR (KBr): ν~=1695 (OCO)asym, 1608 (C=N), 1551, 1473, 1445, 1400 (OCO)sym, 1287, 
1152, 1126, 1082, 914, 879, 840, 819, 758, 701, 639, 564 cm-1; elemental analysis 
calcd (%) for C32H26N2O6Ti: C 65.99, H 4.50, N 4.81; found: C 65.78, H 4.80, N 4.80. 
Synthesis of 6·C6H6. An analogous method to that used for the preparation of 1 was 
followed using titanium(IV) tetra(isopropoxide) (0.25 g, 0.879 mmol), L-tryptophan 
(0.36 g, 1.759 mmol) and 2-hydroxybenzaldehyde (0.21 g, 1.758 mmol), giving red 
crystals of 6 in a yield of 0.39 g, 67%. m.p. 283-286 °C; 1H NMR (400 MHz, CDCl3): 
δ=10.9 (s, 2H; H-14), 7.99 (s, 2H; H-7), 7.43 (t, 2H; H-3), 7.38 (d, 2H; H-5), 7.30-6.80 
(m, 16H; H-13, H-17, H-18, H-19, H-20, and C6H6 solvate), 6.71 (t, 2H; H-4), 6.46 (d, 
2H; H-2), 4.75 (q, 2H; H-9), 3.46 (dd, 2H; H-11a), 3.15 ppm (dd, 2H; H-11b); 13C 
NMR (100 MHz, CDCl3): δ=174.7 (C-10), 163.5 (C-1), 160.8 (C-7), 135.7, 133.2, 
127.4 (C6H6 solvate), 125.9, 124.2, 120.9, 120.8, 120.6, 118.5, 117.4, 114.4, 110.9, 
107.4 (ArC), 75.6 (C-9), 30.1 ppm (C-11); IR (KBr): ν~=3416 (N-H), 1688 (OCO)asym, 
1606 (C=N), 1549, 1442, 1426, 1393 (OCO)sym, 1309, 1276, 1225, 1150, 1125, 1099, 
898, 822, 770, 750, 682, 640, 568 cm-1; elemental analysis calcd (%) for 
C42H34N4O6Ti: C 68.30, H 4.64, N 7.59; found: C 68.33, H 4.88, N 7.60. 
 
Single crystal X-ray structure determination 
For diffraction studies, crystals were stored in silicon oil to avoid crystal deterioration 
by efflorescent de-solvation. Crystal data and refinement details for 1-3, 5, and 6 are 
included in Table 1. Intensity data for the investigated complexes were measured at 
room temperature on an Agilent Xcalibur Eos Gemini diffractometer equipped with a 
CCD area detector and graphite-monochromated Mo Kα radiation (λ = 0.71073 Å). 
Data reduction and empirical absorption corrections, based on a multi-scan 
technique, were applied.[72] The structures were solved by direct methods,[73] and 
refined on F2 with anisotropic displacement parameters and C-bound H atoms in the 
riding model approximation.[74] For 6, the nitrogen-bound H atom was refined with a 
distance restraint N‒H = 0.86 ± 0.01 Å. A weighting scheme of the form w = 1/[σ2(Fo2) 
+ (aP)2 + bP] where P = (Fo2 + 2Fc2)/3) was introduced in each refinement. A 
consequence of the structures being determined at room temperature was the 
presence of large displacement parameters. Nevertheless, the structures were 
determined unambiguously and are in accord with the spectroscopic data. In the 
refinement of 1, the methane-C2‒C3(methyl) residue was statistically disordered and 
each component was refined anisotropically. For 2, the C15-isopropyl group was 
statistically disordered. While each component was refined anisotropically, the 
displacement ellipsoids were restrained to be nearly isotropic. The atoms of the C27-
isopropyl group were also restrained to be nearly isotropic. Owing to poor agreement, 
one reflection, i.e. (3 0 3), was omitted from the final cycles of refinement. The 
absolute structures for 2 and 3 were determined based on differences in Friedel pairs 
included in the data set. At the conclusion of the refinement of 3, evidence for 
disordered solvent was found, as was the presence of voids large enough to 
accommodate solvent. This electron density was modeled with the MASK routine of 
OLEX2;[75] refer to the respective CIF for more details. For 6, the absolute structure 
was determined as for 2 and 3, and the N-bound H atom was refined with the 
distance restraint N‒H = 0.86 ± 0.01 Å and with Uiso = 1.2 Ueq(N). The molecular 
structure diagrams were generated at the 25% probability level by ORTEP for 
Windows,[76] and the packing diagrams were generated with DIAMOND.[77] Additional 
data analysis was made with PLATON.[78]  
 
 
 
 
 
 
 
 
 
Table 1. Crystal data and refinement details for 1-3, 5, and 6. 
[a] The unit cell characteristics do not take into account the unknown solvent within the solvent accessible voids. 
 
 
 
 
 1 2 3 [a] 5 6 
Formula C20H18N2O6Ti C24H26N2O6Ti C26H30N2O6Ti C32H26N2O6Ti C36H28N4O6Ti.C6H6 
Formula weight 430.26 486.34 514.42 582.45 738.63 
Crystal colour orange orange orange orange red 
Crystal size/mm3 0.21 x 0.23 x 0.25 0.12 x 0.15 x 0.23 
0.22 × 0.23 × 
0.23 
0.10 x 0.23 x 
0.25 0.19 x 0.20 x 0.25 
Crystal system Monoclinic Orthorhombic Orthorhombic Monoclinic Tetragonal 
Space group C2/c P212121 P212121 P21/n P43212 
a/Å 18.0072(12) 11.5943(7) 11.5160(3) 11.8347(8) 10.8554(5) 
b/Å 8.5565(6) 19.7512(16) 20.6532(5) 10.3845(8) 10.8554(5) 
c/Å 12.9611(6) 21.7374(19) 23.1511(6) 22.7080(17) 30.210(2) 
α/° 90 90 90 90 90 
β/° 100.182(5) 90 90 98.975(7) 90 
γ/° 90 90 90 90 90 
V/Å3 1965.6(2) 4977.9(7) 5506.3(3) 2756.6(4) 3559.9(4) 
Z 4 8 8 4 4 
Dc/g cm-3 1.454 1.298 1.241 1.403 1.378 
F(000) 888 2032 2160 1208 1536 
µ (MoKα)/mm-1 0.475 0.384 0.350 0.360 0.296 
Measured data 4891 15227 33649 10975 7729 
 θ range/° 3.6 – 28.9 3.5 – 29.1 3.3 – 29.0 3.0 – 29.0 3.8 – 28.9 
Unique data 2300 10264 12535 6302 4060 
Observed data (I ≥ 
2.0σ (I)) 1843 6006 8979 4047 2263 
No. of parameters 152 663 639 370 244 
R, obs. data; all 
data 0.049; 0.064 0.080; 0.138 0.046; 0.073 0.051; 0.092 0.063; 0.132 
a; b in weighting 
scheme 0.065; 1.116 0.120; 0 0.047; 0.005 0.059; 0 0.016; 0 
Rw, obs. data; all 
data 0.127; 0.135 0.194; 0.239 0.092; 0.102 0.112; 0.129 0.070; 0.086 
Range of residual 
electron density 
peaks/eÅ-3 
-0.39 – 0.24 -0.30 – 0.83 -0.20 – 0.28 -0.31 – 0.27 -0.21 – 0.26 
Cell culture and in vitro cytotoxicity 
Ovarian carcinoma A2780 (European Collection of Authenticated Cell Cultures) and 
colorectal adenocarcinoma HT-29 (American Type Culture Collection) cancer cell 
lines were cultured as monolayers in Roswell Park Memorial Institute (RPMI) 1640 
medium, supplemented with 10% fetal bovine serum, 1% L-glutamine, and 1% 
Penicillin-Streptomycin (all purchased from Biological Industries), at 37 °C in a 5% 
CO2 atmosphere. Cytotoxicity was measured by the previously reported MTT 
method.[79] In a standard experiment, cells were seeded in 96-well plates at a density 
of ca. 10000 cells per well and allowed to attach overnight. In the following day, 
compounds 1-6 were dissolved in DMSO (Alfa Aesar) and serially diluted, to create 
10 concentrations of each compound, with pure DMSO as the control. The solutions 
were then diluted further in cell-culture media, to ensure a final concentration of 0.5% 
DMSO, and added to the cells. The plates were incubated under the previously 
described conditions for 72 hours, after which MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide, Sigma Aldrich) was added to the wells (0.1 mg in 20 
µL) for an additional 3 hours incubation period. The medium was removed and 
replaced with 200 µL of isopropanol (Gadot-Group), and upon complete dissolution 
of the formazan, the absorbance was measured at 550 nm using a Spark 10 M 
multimode microplate reader spectrophotometer (Tecan Group Ltd., Mannedorf, 
Switzerland). Each measurement was repeated at least 3 × 3 times: three repeats 
per plate, all repeated on at least three different days, creating at least nine 
repetitions for each experiment. The relative IC50 values and the standard error of 
means were determined by a nonlinear regression of a variable slope (four 
parameters) model using the GraphPad Prism 5.0 software. 
 
 
  
Hydrolytic stability 
The kinetic hydrolytic stability of 1-6 was studied by 1H NMR spectroscopy at 298 K 
using a Bruker AMX 500 spectrometer, as previously described.[44] For each 
compound, an initial spectrum was recorded after dissolving the compound and the 
internal standard, 1,4-dinitrobenzene (Sigma Aldrich), in DMSO-d6 (Cambridge 
Isotope Laboratories, Inc.), to produce a ca. 5 mM solution. Afterwards, >1000 
equivalents of D2O (Cambridge Isotope Laboratories, Inc.) were added to create a 
9:1 DMSO-d6/D2O solution, and a spectrum was recorded immediately. The 
hydrolytic process was monitored by comparing the integration of a selected ligand 
peak at a given time point to its original integration upon the addition of D2O, in 
relation to the internal standard. Compounds 2, 3 and 6 were monitored for 24 hours, 
whereas compounds 1, 4 and 5 were monitored for 3 hours. 
 
Results and discussion 
Synthesis and Characterization 
The present investigation includes Schiff base ligands derived from biologically 
important chiral amino acids for developing potential new titanium(IV)-based 
anticancer agents. To achieve solubility of the starting materials and in situ generated 
Schiff-base ligands, a benzene/methanol mixture was selected as solvent. Ti(IV) 
complexes 1-6 (Scheme 1) were prepared in one pot reaction by employing the 
respective chiral amino acid, 2-hydroxybenzaldehyde, and titanium(IV) 
tetra(isopropoxide) in benzene/methanol. Generally, after 7-8 h {hours are used 
elsewhere}, the reaction was complete as identified by NMR analysis. The 
complexes were isolated as orange (1-5) or red (6) crystalline materials and were 
stable in vacuo, but the crystals turned into powder with time. The IR spectra of 1-6 
show two intense bands in the regions between 1688-1701 and 1393-1402 cm-1 
corresponding to ν(OCO)asym and ν(OCO)sym vibrations, respectively. The observed 
differences between the asymmetric and symmetric vibrations were greater than 200 
cm-1, indicating a monodentate coordination of the carboxylate ligand;[80] this 
assumption was subsequently confirmed by the results of single crystal X-ray 
diffraction studies (vide infra). The 1H NMR and 13C{1H} NMR spectra also supported 
formation of 1-6 (Figures S1-S12).  
 
 
Scheme 1. Preparation of titanium(IV) complexes 1-6 along with the atom numbering 
protocol used for NMR signal assignments (see experimental section). 
 
 
Molecular structures 
The molecular structures of 1-3, 5, and 6 have been established by single crystal X-
crystallography and are illustrated in Figure 1, and selected geometric parameters 
are collated in Table 2.  The titanium(IV) center in 1 is located on a crystallographic 
2-fold axis of symmetry, indicating that the di-negative anions were strictly equivalent.  
The tridentate ligand coordinates via carboxylate-O-, imine-N- and phenoxide-O 
atoms to establish five- and six-membered chelate rings. The Ti‒O1(carboxylate) 
bond length was significantly longer than the Ti‒O3(phenoxide) bond, which 
correlates with the presence of the electronegative-O2(carbonyl) atom bound to the 
quaternary-C1 atom. The disparity in the C1‒O1, O2 bond lengths, i.e. 1.301(3) and 
1.206(3) Å, respectively, clearly indicated a monodentate coordination of the 
carboxylate ligand. The C4═N1 bond length of 1.281(3) Å was consistent with the 
presence of an imine bond. The resultant trans-N2O4 donor set was based on a 
distorted octahedron with the like atoms being in a trans configuration. Both of the 
trans O‒Ti‒O angles deviated by more than 20° from the ideal 180°. The Ti‒O1‒C1 
[125.50(17)°], Ti‒O3‒C10 [137.54(15)°], and Ti‒N1‒C4 [126.76(16)°] angles all 
exceed 120°, especially the one subtended at the phenoxide-O3 atom. Neither of the 
five- or six-membered chelate rings was planar. For the former, the r.m.s. deviation of 
the O1, C1, C2 and N1 atoms was 0.0847 Å. The Ti atom lies 0.150(5) Å out of the 
plane and may be considered as the flap atom in an envelope conformation. The 
envelope conformation was more pronounced for the six-membered chelate ring with 
the r.m.s. deviation for the O3, C10, C5, C4, and N1 atoms being 0.0285 Å and with 
the Ti atom lying 0.391(3) Å out of the plane. As a first approximation, the tridentate 
ligand may be considered planar as the dihedral angle formed between the best 
planes through the chelate rings was 8.50(14)°. Four other structures in the series 
were obtained. In 2 and 3, two independent molecules comprise the asymmetric unit, 
whereas in 6, the molecule has 2-fold symmetry. Complex 2 has also been 
characterized previously as a dichloromethane solvate.[81] In this literature structure, 
designated 2', the molecule has 2-fold symmetry. 
 
 
 
 
 
 
 Figure 1. Molecular structures of 1, 2a (the imine-C6 atom is obscured), 3a, 5, and 6 
(benzene molecule omitted) showing atom labeling schemes and anisotropic 
displacement parameters at the 25% probability level (refer to Figure S13 for 2b and 
3b). The titanium atom in each of 1 and 6 lies on a crystallographic 2-fold axis of 
symmetry.  Unlabeled atoms are related by the symmetry operation 1-x, y, 1½-z (1) 
and 1-y, 1-x, ½-z (6). 
 
 
 
 
 
 
 
  
Figure 2. Overlay diagrams showing molecules of 2a (red image) and 2b (inverted, 
blue), molecules of 3a (red image) and 3b (blue), and of all molecules: 1 (red image), 
2a (blue), 2b (inverted; green), 3a (pink), 3b (yellow), 5 (aqua), 6 (grey) and 2' (Hu 
2001,[73] olive green); molecules have been overlapped so that one of the carboxylate 
residues in each molecule is coincident. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Selected geometric parameters (Å, °) for complexes 1-3, 5, and 6. 
 
 
 
 
[a] The molecule in each of 1 and 6 has crystallographic 2-fold symmetry so both ligands have identical 
parameters. [b] For 2b and for 3b, add “6” to the atom labels for the oxygen atoms and “2” for nitrogen 
atoms. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Complex 
Parameter 
1[a] 2a 2b[b] 3a 3b[b] 5 6[a] 
Ti‒O1 1.946(2) 1.934(5) 1.931(6) 1.953(2) 1.940(2) 1.9199(17) 1.946(3) 
Ti‒O3 1.850(2) 1.847(5) 1.838(6) 1.857(2) 1.842(2) 1.8345(16) 1.840(3) 
Ti‒N1 2.140(2) 2.159(6) 2.155(7) 2.143(3) 2.141(3) 2.1573(18) 2.140(3) 
Ti‒O4 1.946(2) 1.922(6) 1.936(6) 1.939(2) 1.951(2) 1.9382(17) 1.946(3) 
Ti‒O6 1.850(2) 1.853(5) 1.849(7) 1.846(2) 1.840(2) 1.8455(16) 1.840(3) 
Ti‒N2 2.140(2) 2.147(6) 2.147(7) 2.154(3) 2.146(3) 2.1145(18) 2.140(3) 
O1‒Ti‒O3 159.13(7) 158.3(3) 157.8(3) 158.1(1) 159.1(1) 158.51(7) 158.9(1) 
O1‒Ti‒O3 89.6(1) 88.1(2) 90.6(3) 90.8(1) 88.2(1) 91.28(8) 91.0(2) 
O1‒Ti‒N1 75.72(7) 76.2(2) 75.6(3) 75.2(1) 75.8(1) 75.92(7) 75.7(1) 
O3‒Ti‒N1 83.52(7) 82.2(2) 82.6(3) 82.9(1) 83.3(1) 82.94(7) 83.4(1) 
O4‒Ti‒O6 159.13(7) 158.3(3) 157.8(3) 158.2(1) 158.6(1) 157.56(7) 158.9(1) 
O4‒Ti‒N2 75.72(7) 76.1(2) 75.7(3) 75.8(1) 75.9(1) 75.62(7) 75.7(1) 
O6‒Ti‒N2 83.52(7) 82.3(2) 82.1(3) 82.5(1) 82.7(1) 82.22(7) 83.4(1) 
N1‒Ti‒N2 169.63(1) 165.4(2) 164.0(2) 164.4(1) 165.5(1) 167.52(7) 159.8(2) 
The independent molecules in 2, i.e. 2a and 2b, differed non-trivially, exhibiting 
differences in the relative orientations of the peripheral groups as may be seen from 
the overlay diagram in Figure 2; the same comments pertain to the two molecules in 
3. Despite these differences, no systematic trends between 2a and 2b nor between 
3a and 3b were evident in terms of the derived interatomic parameters, Table 2 and 
ESI Table S1. Across the series, the most planar five-membered chelate ring was 
found for the O1-ring in 2b while the most distorted was found in 1 (both rings). For 
the six-membered chelate rings, the most planar was found in 2a (O3-ring) and the 
most distorted in 5 (O4-ring, second molecule). In terms of deviations of the titanium 
atom from the planes of the other atoms comprising the five-membered rings, the 
metal was close to co-planar with the four atoms in 6 (O3-ring) and exhibited the 
greatest deviation in 5 (O4-ring, second molecule), see ESI Table S1. The minimum 
and maximum deviations of the titanium atom from the five other atoms of the six-
membered chelate rings was found in 2a (O3-ring) and 5 (O3-ring), respectively. No 
systematic variations in the geometric parameters were evident across the series of 
molecules. In terms of the dihedral angles between the chelate rings, the greatest 
dihedral angle of 17.51(10)° was found for one of the ligands in 5 and the smallest, 
i.e. 2.64(8)°, was also found in 5. The conformational flexibility in this series of 
structures is highlighted in the overlay diagrams of Figure 2. 
An important aspect of the crystallographic analysis worth commenting upon 
is the apparent racemization that has occurred during crystallization. The syntheses 
were conducted on authenticated chiral Schiff bases derived from various amino 
acids. Crystals of 1 and 5 were found to adopt centrosymmetric space groups, 
whereas those of 2, 3, and 6 were found in chiral space groups. Similar behavior was 
noted in the crystal chemistry of several diorganotin(IV) Schiff base derivatives 
derived from L-tyrosine.[82] 
One other crystalline sample was obtained, namely of compound 4, but unresolvable 
issues in the refinement precluded detailed reporting of the structure.[83] The 
preliminary structural study of 4, derived from L-leucine, suggested that five 
independent molecules comprised the asymmetric unit, and each of these also 
adopted the isomeric form akin to 2a. Also noteworthy is that 4 crystallized in the 
non-centrosymmetric space group P212121. 
 
Molecular packing 
In the absence of conventional hydrogen bonding interactions, molecules in the 
crystals of 1-3 and 5 were connected by various non-covalent interactions, whereas 
conventional N‒H…O hydrogen bonding was noted in the crystal of 6. The geometric 
parameters characterizing the specified intermolecular interactions in the following 
discussion are collated in the respective figure captions (ESI Figures S14-S18). 
In the molecular packing of 1, molecules were connected into supramolecular 
layers in the bc-plane by π-stacking between phenyl rings as well as methine-C‒
H…π(phenyl) interactions. The carbonyl-O2 atoms protruded to either side of the 
layer (ESI Figure S14a), and these were pivotal in linking layers along the a-axis via 
methyl- and phenyl-C‒H…O(carbonyl) interactions (see ESI Figure S14b for the unit 
cell contents of 1).  In the crystal of 2, similar interactions were evident between the 
independent molecules: π-stacking between the phenyl rings, combined with phenyl-
C‒H…π(phenyl) and imine-C‒H…O(carbonyl) interactions, which lead to the formation 
of supramolecular chains along the c-axis (ESI Figure S15a). The chains were linked 
into a three dimensional architecture by phenyl-C‒H…O(carbonyl) contacts (see ESI 
Figure S15b for the unit cell contents of 2). Similar types of contacts pertained in the 
crystal of 3, which accommodated an undetermined solvent in the voids defined by 
the complex molecules. Contacts of the type imine-, methyl-, and phenyl-C‒
H…O(carbonyl), π(phenyl)…π(phenyl), and phenyl-C‒H…π(phenyl), linked the 
molecules into a three dimensional architecture (ESI Figure S16). 
Supramolecular layers parallel to (-1 0 1) were evident in the molecular packing of 5 
(ESI Figure S17a). The connections between the molecules were of the type imine-, 
phenyl-, and methylene-C‒H…O(carbonyl), methane-C‒H…π(phenyl), and carbonyl-
C=O…π(phenyl). While not common, carbonyl-C=O…π(phenyl) and related O(lone-
pair)…π(arene) interactions are known to be important in assembling molecules in 
crystals.[84-86] In the present case and as illustrated in Figure 3, centrosymmetric, 
supramolecular dimers formed, which is the commonly adopted motif stabilized by 
such interactions. In the crystal of 5, layers stacked without directional interactions 
between them (see ESI Figure S17b for the unit cell contents of 5). In the crystal of 6, 
both complex and solvent (benzene) molecules were present, in a 1:1 ratio, and a 
1H-indolyl residue presented the opportunity for conventional hydrogen bonding. 
Indeed, weak indolyl-N‒H…O(carboxylate) hydrogen bonding was observed and as, 
from symmetry, each complex molecule formed two donor and two acceptor 
interactions, the hydrogen bonding served to stabilize the three dimensional 
architecture. Supporting phenyl-C‒H…O(carbonyl) and phenyl-C‒H…π(phenyl) 
interactions contributed to the stability of the molecular packing. The solvent benzene 
molecules resided in channels along the a-axis direction with no directional 
interactions between the complex and solvent molecules (see ESI Figure S18 for the 
unit cell contents of 6). 
 
Figure 3. Supramolecular aggregate in the crystal of 5 stabilized by carbonyl-
C=O…π(phenyl) interactions, shown as red dashed lines. For reasons of clarity, non-
participating hydrogen atoms are removed. 
 
 
Photophysical properties 
The photophysical properties and the fluorescent processes have been reviewed 
recently which are largely concentrated on the complexes of mid to late transition 
metals.[87] With the well-characterized series of octahedral titanium(IV) complexes (1-
6) in hand, their photophysical properties were of interest. Representative spectral 
profile of 1-6 in solution and in the solid state is depicted in Figure 4. The absorption 
spectra of the compounds in acetonitrile and DMSO solutions show two peaks 
centered at ~300 and ~360 nm. The absorption spectral profile was particularly 
insensitive to the nature of substitution of the ligand (Figure 4(a)). Excitation at 300 
nm produced a broad and unstructured emission at 390 nm for most of the 
complexes in acetonitrile, with exception of 1 and 3, in which the fluorescence peak 
appeared at 440 nm (Figure 4(b)). However, excitation at the lower energy 
absorption band (360 nm) produced a very broad emission band within the 390–540 
nm range, with a peak position at 440 nm (Figure 4(d)). The spectral peak positions 
for 1-6 along with the calculated fluorescence yields (φf) in acetonitrile are given in 
Table 3. Fluorescence relaxation dynamics in a nanosecond time domain was also 
measured in acetonitrile exciting by 295 and 365 nano-LED and monitoring the 
emission at the respective fluorescence maximum (Figures 4(e) and 4(f)). The 
fluorescence decays were mostly non exponential in both cases. Individual 
contribution of different decay components in each case is also incorporated in Table 
3. At 295 nm excitation, the fastest decay component (τ1 = 0.5-1.5 ns) contributed 
the most (50-90%), while the long decay component (τ3 > 5.0 ns) showed an 
insignificant contribution (only 5-10%). Overall, the average fluorescence decay time 
(τavg) for the complexes was within 3.2-4.6 ns for the 340 nm emission (λex = 295 
nm), whereas the corresponding decay time of 0.5-1.2 ns was observed for the 440 
nm emission (λex = 365 nm). Interestingly, the photoluminescence behavior is 
strikingly different for the complexes when measured in DMSO solution. The principle 
fluorescence peaks for the complexes appeared at 440 nm when excited at 300 and 
360 nm (Figure 4(c)). The 340 nm emission appeared as a mere hump when the 
fluorescence emission was collected by excitation at 300 nm. The spectral behavior 
along with the details of time resolved measurements for 1-6 in DMSO are provided 
in ESI Figure S19 and ESI Table S2. Notably, the average fluorescence lifetime of 
440 nm emission increased significantly (τavg = 2.7-4.8 ns) in the DMSO solution. The 
solid-state photoluminescence spectra of 1-6 displayed a broad band in the ~550-
570 nm region (Figure 4(g)). The bi-exponential fluorescence decay kinetics (Figure 
4(h)) comprised a major component with a very fast time constant of 600-700 ps, and 
a very small contribution (<1%) with a lifetime of 7-9 ns (Table 3). The average 
fluorescence decay time in the solid state (0.6-1.0 ns) was much faster than in 
solution, which signifies appreciable stabilization of the excited state in the latter 
case. 
 
Figure 4. Photophysical properties of 1-6 at various experimental conditions. 
Absorption spectra (a). Emission spectra; λex = 295 nm in acetonitrile (b) λex = 295 nm 
in DMSO (c) and λex= 365 nm in acetonitrile (d). Fluorescence decay traces in 
acetonitrile excited at 295 nm (e) and 365 nm (f). Fluorescence emission (g) and 
time-resolved fluorescence decay (h) of 1-6 in the solid state. 
(b) 
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Table 3. Photophysical parameters for 1-6 in acetonitrile solution and in solid state. 
 
Steady state 
Complex 
In acetonitrile In solid-state 
maxλabs /nm maxλem /nm ɸf maxλem /nm 
1 297, 363 440 0.011 566 
2 297, 369 434 0.002 558 
3 300, 366 433 0.008 561 
4 297, 365 434 0.007 559 
5 297, 364 437 0.014 557 
6 297 ,360 434 0.002 595 
Time resolved fluorescence decay in acetonitrile 
 λex: 295 nm; λmon: 340 nm    λex: 365 nm; λmon: 435 nm 
 α1 (%) τ1 /ns α2 (%) τ2 /ns α3 (%) τ3 /ns τav ns α1 (%) τ1 /ns α2 (%) τ2 /ns τav /ns 
1 75.45 0.56 14.77 3.76 9.82 6.84 4.20 88.47 1.38 11.53 4.28 2.21 
2 87.11 0.86 12.89 5.70   3.25 85.02 0.98 14.98 2.10 1.29 
3 79.53 0.71 20.47 5.66   4.03 93.85 1.01 6.15 4.41 1.77 
4 76.78 0.57 18.28 4.47 4.95 8.13 4.34 76.93 0.15 23.04 1.57 1.22 
5 72.79 0.55 15.99 3.92 11.22 7.11 4.57 79.53 0.28 20.47 1.82 1.24 
6 48.28 1.47 51.72 5.21   4.43 99.31 0.21 0.69 2.75 0.42 
Time resolved fluorescence decay in the solid state; λex: 365 nm; λmon: 560-590 nm 
 α1 (%) τ1 /ns α2 (%)  τ2 /ns τav /ns 
1 99.74 0.69 0.13 9.46 0.84 
2 99.87 0.60 0.13 9.20 0.77 
3 99.75 0.64 0.25 10.06 1.00 
4 99.86 0.60 0.14 7.47 0.72 
5 99.74 0.63 0.26 8.52 0.90 
6 99.97 0.69 0.26 10.04 1.03 
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Cytotoxicity and hydrolytic stability 
The cytotoxicity of 1-6 toward two human cancer cell lines, the ovarian carcinoma 
A2780 and the colorectal adenocarcinoma HT-29, was assessed by the previously 
reported MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay.[79] 
The dose response curves are depicted in Figure 5, and the relative IC50 values are 
summarized in Table 4. 
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Figure 5. Dependence of A2780 (left) and HT-29 (right) cell viability on the 
administered concentration of 1-6, as measured by the MTT assay following a three 
day incubation period. 
 
Table 4. IC50 values toward the human A2780 and HT-29 cancer cell lines, and t1/2 
for hydrolysis values of 1-6. 
Complex 
IC50 (µM) t1/2 for hydrolysis 
(hours) A2780 HT-29 
1 30 ± 8 60 ± 10 0.7 ± 0.1 
2 28 ± 2 60 ± 3 9.5 ± 0.4 
3 23 ± 2 36.2 ± 0.4 15 ± 2 
4 48 ± 3 81 ± 4 1.18 ± 0.05 
5 37 ± 7 89 ± 9 1.67 ± 0.07 
6 29 ± 3 103 ± 9 5.7 ± 0.1 
 
All tested compounds were cytotoxic, with similar reactivity toward both lines. As 
expected, the ovarian line was more sensitive than the colorectal line for all 
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compounds tested.[31,48] The IC50 values were mostly in the same order of magnitude 
as those obtained for cisplatin,[88] or one order higher, with 3 as the most potent 
compound toward both cell lines. 
The comparative hydrolytic stability of 1-6 was assessed by 1H NMR, with 1,4-
dinitrobenzene as an internal standard, as previously described.[44] The half-life 
values toward hydrolysis upon the addition of 10% D2O are summarized in Table 4 
(See ESI Figures S20 and S21). Whereas 1, 4, and 5 exhibited relatively low 
stabilities, with t1/2 values of around 1 h, compounds 2, 3, and 6 were stable for 
longer periods, up to t1/2 of 15 h for the most stable compound, 3. These stabilities 
are lower than those previously obtained for related systems that are based on 
phenolato/alkoxo ligands.[29,34,44,49,51,54] This may be attributed to weaker binding of 
the carboxylate ligand, as observed previously.[89] 
Inspecting the overall data, 3 is identified as both the most active and the most stable 
of the six compounds. The high stability may be attributed to the larger steric bulk, 
inhibiting interactions with water molecules.[39,44,47] This hypothesis is further 
supported when inspecting other complexes, whereby larger steric bulk near the 
metal center translates to higher stability, with lowest stability for the smallest 
methylated compound 1. Nevertheless, no clear correlation between activity and 
stability is detected for the rest of the complexes, and especially as some highly 
unstable complexes are still cytotoxic, it is reasonable that hydrolysis products may 
serve as active species in the cell, as reported previously.[34,35,39,42,90] It is possible 
that the least stable 1, featuring smallest steric bulk, may yield small enough 
hydrolysis products that can penetrate through the cell membrane and demonstrate 
activity. Interestingly, 2, 3, and 6 were more soluble in DMSO than 1, 4, and 5, which 
correlates with their higher stability, but not necessarily higher cytotoxicity.   
 
Conclusions 
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Six titanium(IV) complexes based on tridentate ONO-type Schiff base ligands derived 
from chiral amino acids were synthesized and fully characterized. X-ray 
crystallography established a trans-N2O4 donor set defined by carboxylate-O-, imine-
N- and phenoxide-O atoms of two di-anionic, tridentate ligands. Photoluminescence 
behavior of the complexes was significantly different in DMSO and in acetonitrile. 
Further, excited state relaxation was much faster in the solid state than in solution. 
These complexes represent a new family of anticancer Ti(IV) compounds, with 
marked activity toward colon and ovarian human cancer cell lines.[48] Similar ligands 
to those used herein were previously employed on metals such as Sn(IV), resulting 
in highly antineoplastic compounds.[70-71] The mediocre hydrolytic stability recorded 
for the complexes implies that some hydrolysis takes place in the cellular 
environment, and additional studies are required to fully elucidate the nature of the 
active species.  
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TOC: 
 
Six homoleptic Ti(IV) complexes containing amino-acid tethered phenolato ligands 
were synthesized and characterized spectroscopically and crystallographically. The 
complexes displayed marked cytotoxicity toward human ovarian and colon cancer 
cells, with mediocre stability in 10% D2O solutions, overall pointing to steric bulk as a 
contributor to stability and solubility. 
